Starting this week, two new drugs – tocilizumab and sarilumab –will become a standard part of NHS treatment for Covid-19 patients admitted to intensive care.
A personal view from Ian Stewart, Deloitte’s Chief Economist in the United Kingdom. Covid-19 case rates are rising while fatalities remain relatively low across much
Subscribe to Reaction and receive unlimited access to the site, our daily email with analysis every evening and invites to online events.
© Copyright 2023 Reaction Digital Media Limited – All Rights Reserved. Registered Company in England & Wales – Company Number: 10166531.
